Literature DB >> 24218420

Monitoring of unfractionated heparin in critically ill patients.

R Aarab1, J van Es, A C J M de Pont, M B Vroom, S Middeldorp.   

Abstract

BACKGROUND: In critically ill patients, dosing of unfractionated heparin (UFH) is difficult due to unpredictable pharmacokinetics, which has an impact on the time to reach therapeutic anticoagulation. We evaluated the quality of UFH therapy in critically ill patients in terms of activated partial thromboplastin time (APTT) test values and time to therapeutic range.
METHODS: Patients admitted to the Intensive Care Unit (ICU) and Medium Care Unit (MCU) were screened for intravenous UFH administration. Time to therapeutic range was categorised into 0-12, 13-24 and >24 hours. APTT results were classified into categories of subtherapeutic, supratherapeutic and therapeutic tests. We identified to what extent the sub- and upratherapeutic values were aberrant of the limit of the therapeutic range (15%).
RESULTS: In 101 patients admitted to the ICU and MCU, time to therapeutic range was 24 hours in 56% of the population, whereas in 10% of the patients no therapeutic APTT was achieved during UFH treatment. Among the APTT levels, 29% of all test results measured in 24 hours were within the therapeutic range. Subtherapeutic values were found in 53% of the test results, of which 160/203 were more than 15% under the lower limit, whereas 18% of the test results were supratherapeutic, of which 40/69 more than 15% above the upper limit.
CONCLUSION: In this cohort of critically ill patients, therapeutic APTT values were reached within 24 hours in 56% of the patients. We conclude that intravenous UFH therapy can be improved in critically ill patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24218420

Source DB:  PubMed          Journal:  Neth J Med        ISSN: 0300-2977            Impact factor:   1.422


  6 in total

1.  Monitoring Anticoagulation with Unfractionated Heparin on Renal Replacement Therapy. Which is the Best aPTT Sampling Site?

Authors:  Florin Ioan Anton; Paul Adrian Rus; Natalia Hagau
Journal:  J Crit Care Med (Targu Mures)       Date:  2020-08-11

2.  Advances in the treatment of cerebral venous thrombosis.

Authors:  J M Coutinho; S Middeldorp; J Stam
Journal:  Curr Treat Options Neurol       Date:  2014-07       Impact factor: 3.598

3.  Citrate anticoagulation versus systemic heparinisation in continuous venovenous hemofiltration in critically ill patients with acute kidney injury: a multi-center randomized clinical trial.

Authors:  Louise Schilder; S Azam Nurmohamed; Frank H Bosch; Ilse M Purmer; Sylvia S den Boer; Cynthia G Kleppe; Marc G Vervloet; Albertus Beishuizen; Armand R J Girbes; Pieter M Ter Wee; A B Johan Groeneveld
Journal:  Crit Care       Date:  2014-08-16       Impact factor: 9.097

4.  Pharmacokinetics and dialytic clearance of apixaban during in vitro continuous renal replacement therapy.

Authors:  Lauren Andrews; Scott Benken; Xing Tan; Eric Wenzler
Journal:  BMC Nephrol       Date:  2021-01-30       Impact factor: 2.388

5.  Monitoring of Unfractionated Heparin Therapy in the Intensive Care Unit Using a Point-of-Care aPTT: A Comparative, Longitudinal Observational Study with Laboratory-Based aPTT and Anti-Xa Activity Measurement.

Authors:  Benjamin Lardinois; Michaël Hardy; Isabelle Michaux; Geoffrey Horlait; Thomas Rotens; Hugues Jacqmin; Sarah Lessire; Pierre Bulpa; Alain Dive; François Mullier
Journal:  J Clin Med       Date:  2022-02-28       Impact factor: 4.241

6.  System performance evaluation of the cobas t 711 and cobas t 511 coagulation analyzers in routine laboratory settings.

Authors:  Steve Kitchen; Moniek de Maat; Michael Nagler; Robert Jones; Anna Lowe; John Burden; Kai Groneberg; Gergely Rozsnyai
Journal:  Blood Coagul Fibrinolysis       Date:  2020-10       Impact factor: 1.061

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.